The Plasma Protein Therapeutics Association (PPTA) welcomes EU Health Commissioner Kyriakides’ recognition of the importance of plasma donation in her observance yesterday of World Blood Donor Day. By noting plasma’s role in the manufacture of plasma-derived medicinal therapies (PDMPs) for people with a range of life-challenging diseases, as well as its potential role in treating people with COVID-19, Commissioner Kyriakides rightly notes that “donating plasma is therefore now more important than ever.”

May 28, 2020 (Brussels, Belgium)  — The Plasma Protein Therapeutics Association (PPTA) is concerned about the recommendations contained in 20th version of Blood Guide of The European Directorate for the Quality of Medicines (EDQM) which aims to harmonise standards and recommendations on blood collection, preparation, and the use of blood and blood components. This Guide, if applied, will have a negative impact on the availability of plasma to develop Plasma-Derived Medicinal Products (PDMPs) for European patients as it fails to distinguish between requirements for transfusable blood components and plasma for manufacturing, especially concerning donor deferrals.

April 24, 2020 — (Annapolis, MD) — The Plasma Protein Therapeutics Association (PPTA) applauds the Administration for comments made during the April 23 White House Coronavirus Task Force briefing in which Americans were encouraged to contact their local plasma donation center to learn how they can help. There are currently more than 800 plasma donation centers across the United States, many of which are now collecting plasma from recovered COVID-19 patients, as well as source plasma relied upon by thousands of people living with serious, rare, and often life-threatening conditions. Donation centers can be found by visiting www.donatingplasma.org.

New report analyses clinical, economic, and societal perspectives for patient access

12 March 2020—(Brussels, Belgium)—The Plasma Protein Therapeutics Association (PPTA) recognizes Vintura, a leading consultancy specializing in healthcare and life sciences, for publishing “Key Economic and Value Considerations for Plasma-Derived Medicinal Products in Europe.” The report provides a critical investigation into the clinical, economic, and societal dimensions of PDMPs, with a focus on improving patient access to these lifesaving medicines.

The European Commission and the European Directorate for the Quality of Medicines (EDQM) recently published recommendations on plasma supply management in Europe. The recommendations were drafted by a working group of transfusion specialists representing national blood services (also called the TS093 working group). PPTA thanks the EDQM and the European Commission for addressing this important issue but is concerned that the recommendations do not go far enough towards ensuring the collection of sufficient plasma to meet the growing clinical need for plasma-derived medicinal products (PDMPs). 

The Plasma Protein Therapeutics Association (PPTA) announced today that Maarten Van Baelen has joined the association as Executive Director, PPTA Europe. Maarten brings to PPTA more than 10 years in the life sciences arena, including as an advocate for access to generic, biosimilar and value-added medicines.  He has represented the pharmaceutical sector’s interest in public forums, strategic policy development, and advocacy on key issues with the European Commission, National Competent Authorities, and other stakeholders.

Annapolis, MD (January 14, 2019) -- The Board of Directors of the Plasma Protein Therapeutics Association (PPTA) announced today that Amy Efantis will be its next President and Chief Executive Officer effective January 16, 2019.

Having served most recently as Vice President, Global Public Policy & Government Affairs at Biogen, Efantis joins the PPTA, the world’s leading trade association that represents more than 750 human plasma collection centers in North America and Europe as well as the manufacturers of life-saving plasma protein therapies.

ANNAPOLIS, MD (October 8, 2018) — Today, in conjunction with its member companies, the Plasma Protein Therapeutics Association (PPTA) launched the sixth annual International Plasma Awareness Week (IPAW), a globally recognized opportunity to raise awareness of plasma collection and how lifesaving plasma protein therapies are derived from plasma donations.

“How Is Your Day?” highlights value of plasma protein therapies in improving patients’ lives

Budapest, HUNGARY (March 13)– The Plasma Protein Therapeutics Association (PPTA) today unveiled its new global initiative, “How Is Your Day?” –Making the difference with plasma proteins, in conjunction with the annual International Plasma Protein Congress. “How Is Your Day?” will focus on differentiating these unique therapies from traditional pharmaceuticals and building awareness of the value they provide for people living with rare, life-threatening, chronic, and genetic diseases.

Annual IPAW celebration calls attention to importance of plasma donation to save lives
ANNAPOLIS, MD (October 12, 2017) — The Plasma Protein Therapeutics Association (PPTA) applauds Representative Doris Matsui (CA-6) for recognizing International Plasma Awareness Week (IPAW) with a statement in the Congressional Record noting these therapies “save and improve lives of individuals throughout the world [and] have significantly improved the quality of life, markedly improved patient outcomes, and extended the life expectancy of individuals with rare, chronic diseases and conditions.”